Compare TMP & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMP | DRTS |
|---|---|---|
| Founded | 1836 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 1996 | 2021 |
| Metric | TMP | DRTS |
|---|---|---|
| Price | $97.79 | $14.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $87.00 | $8.67 |
| AVG Volume (30 Days) | 77.6K | ★ 573.3K |
| Earning Date | 04-24-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 126.16 | N/A |
| EPS | ★ 3.86 | N/A |
| Revenue | ★ $75,742,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.94 | $699.98 |
| P/E Ratio | $25.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $61.88 | $3.43 |
| 52 Week High | $102.59 | $15.10 |
| Indicator | TMP | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 49.81 | 55.77 |
| Support Level | $96.56 | $11.24 |
| Resistance Level | $102.30 | $14.75 |
| Average True Range (ATR) | 2.05 | 0.57 |
| MACD | -0.45 | -0.12 |
| Stochastic Oscillator | 35.47 | 46.21 |
Tompkins Financial Corp is a Financial Holding Company. The company manages its operations through two business segments, consisting of banking and wealth management. It offers various products and services, including commercial and consumer banking, leasing, trust and investment management, financial planning and wealth management, and insurance. Wealth management activities include the results of the company's trust, financial planning, and wealth management services. The company generates the majority of its revenue from the Banking segment.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.